As-Is Presentation. Arbor Pharmaceuticals, Inc. makes no warranty or representation of any kind as to the information or materials on our website. Access to and use of our website and the content thereof is at your own risk. To the maximum extent permitted by law, Arbor Pharmaceuticals, Inc. disclaims any and all warranties, express or implied, including warranties of merchantability, title, and fitness for a particular purpose. Neither Arbor Pharmaceuticals, Inc. nor any party involved in creating, producing, hosting or delivering this website or its contents shall be liable for any damages, including without limitation: direct, incidental, consequential, indirect, or punitive damages arising out of access to, use of or inability to use the website, or any errors or omissions in the content thereof. This limitation includes damages arising from any viruses or other harmful code that may infect your computer equipment or from malicious persons who may make unauthorized use of the website or its contents.
Medical Information. Our website may contain general medical or healthcare information that is provided for informational purposes only and should not be used in any way for medical diagnosis or treatment. The information provided on this website should be verified by a healthcare professional for accuracy, currency, completeness, and applicability to your situation before being relied upon. You should always obtain advice provided by a doctor or other qualified healthcare professional.
Use of Ideas You Communicate. In the event and to the extent that you have any right, title, or interest in any intellectual property contained in any communication to us, including (without limitation) moral rights, you hereby grant to Arbor Pharmaceuticals, Inc. a worldwide, non-exclusive, transferable, royalty-free, fully paid-up license to use, execute, perform, display, reproduce, modify, distribute, sell, have sold, make, have made, import, export, and create derivative works that Arbor Pharmaceuticals, Inc. will own, and to authorize others to do any of the same, for whatever purpose that Arbor Pharmaceuticals, Inc. may choose and under all rights, title, and interest that you have, including (without limitation) all intellectual property and moral rights.
Trademarks. All product names, whether or not appearing in large print or with the trademark symbol, and all product logos, are trademarks of Arbor Pharmaceuticals, Inc., its affiliates, related companies, or its licensors or joint venture partners, unless otherwise noted. The use or misuse of these trademarks or any other materials, except as expressly permitted herein, and strictly within the limitations of any such permission, is expressly prohibited and may be in violation of copyright law, trademark law, the law of slander and libel, the law of privacy and publicity, and communications regulations and statutes.
Copyrights. The entire contents of this website are subject to copyright protection. Copyright © 2014 Arbor Pharmaceuticals, Inc. All rights reserved. The contents of this website may not be copied other than for non-commercial individual reference with all copyright or other proprietary notices retained, and thereafter may not be recopied, reproduced or otherwise redistributed. Except as expressly provided above, you may not otherwise copy, display, download, distribute, modify, reproduce, republish or retransmit any information, text or documents contained in this website or any portion thereof in any electronic medium or in hard copy, or create any derivative work based on such images, text or documents, without the express written consent of Arbor Pharmaceuticals, Inc.. Nothing contained herein shall be construed as conferring by implication, estoppel, or otherwise any license or right under any patent or trademark of Arbor Pharmaceuticals, or any third party.
Void Where Prohibited. This website and its contents are intended to comply with the laws and regulations in the United States. While available outside the United States, the content of this website as it pertains to pharmaceutical products is intended for use only by residents of the United States. The laws and regulations of other countries may be different. Any offer for any product or service made on our website is void where prohibited by law.
Copyright © 2014 Arbor Pharmaceuticals, Inc.
Important information about BiDil®
(isosorbide dinitrate/hydralazine hydrochloride):
INDICATIONS AND USAGE
BiDil is indicated for the treatment of heart failure as an adjunct to standard therapy in self-identified black patients to improve survival, to prolong time to hospitalization for heart failure, and to improve patient-reported functional status. There is little experience in patients with NYHA class IV heart failure. Most patients in the clinical trial supporting effectiveness (A-HeFT) received a loop diuretic, an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker, and a beta blocker, and many also received a cardiac glycoside or an aldosterone antagonist.
IMPORTANT SAFETY INFORMATION
BiDil is contraindicated in patients who are allergic to organic nitrates.
WARNINGS AND PRECAUTIONS
Augmentation of the vasodilatory effects of isosorbide dinitrate by phosphodiesterase inhibitors such as sildenafil, vardenafil, or tadalafil could result in severe hypotension. The time course and dose dependence of this interaction have not been studied. Reasonable supportive care should consist of those measures used to treat a nitrate overdose with elevation of the extremities and central volume expansion.
Treatment with hydralazine hydrochloride may produce a clinical picture simulating systemic lupus erythematosus including glomerulonephritis. If systemic lupus erythematosus-like symptoms occur in patients treated with BiDil, discontinuation of BiDil should be considered only after a thorough benefit-to-risk assessment. Symptoms and signs of systemic lupus erythematosus usually regress when hydralazine hydrochloride is discontinued but residua have been detected many years later. Long-term treatment with steroids may be necessary.
Symptomatic hypotension, particularly with upright posture, may occur with even small doses of BiDil. BiDil should be used with caution in patients who may be volume depleted or who are already hypotensive.
Hydralazine hydrochloride can cause tachycardia potentially leading to myocardial ischemia and angina attacks. Careful clinical and hemodynamic monitoring is recommended when BiDil is administered to patients with acute myocardial infarction to avoid the hazards of hypotension and tachycardia.
Hydralazine hydrochloride has been associated with peripheral neuritis, evidenced by paresthesia, numbness, and tingling, which may be related to an antipyridoxine effect. Pyridoxine should be added to BiDil therapy if such symptoms develop.
Isosorbide dinitrate therapy may aggravate angina associated with hypertrophic cardiomyopathy.
Headache and dizziness were the most frequent adverse events occurring at an incidence greater than 2% in clinical studies compared to placebo. Others included chest pain, asthenia, nausea, bronchitis, hypotension, sinusitis, ventricular tachycardia, palpitations, hyperglycemia, rhinitis, paresthesia, vomiting, amblyopia, hyperlipidemia, and tachycardia.
The full Prescribing Information for BiDil is available here.